PamBio

Company Overview

Snapshot

Founded in April 2014 by Abd Al-Roof Higazi and Dr. Nuha Higazi, PamBio operated with 1–10 employees. The company raised a total of $10M across two funding rounds. In July 2016, PamBio secured $7M in its latest funding round.

Business overview

PamBio is a biotechnology company focused on developing drug therapies for acute bleeding conditions, including hemorrhagic stroke (intracranial bleeding and ICH). The company's core technology involves an inactive recombinant mutant-tPA protein designed to be a competitive inhibitor to native-tPA, offering dual antifibrinolytic and neuroprotective effects. This therapeutic biomolecule aims to block tPA and uPA fibrinolysis enzyme activity, extending treatment windows beyond three hours, and to limit neurotoxicity by blocking the binding of neurotoxic tPA to NMDA receptors. PamBio operates within the Health Tech & Life Sciences sector, specifically targeting the pharmaceutical and drug development industries globally.

Strategic signal

In March 2017, a co-founder of PamBio highlighted the company's unique position in the market, stating that PamBio was the only entity with a treatment capable of stopping cerebral hemorrhage. This statement underscored the potential for PamBio's innovative drug therapy to address a critical unmet medical need in acute bleeding conditions, signaling a strong value proposition for investors and the medical community.

Company Intelligence Q&A

What is PamBio's primary focus?

PamBio is a biotechnology company developing drug therapy for hemorrhagic stroke and other acute bleeding conditions.

When was PamBio founded and by whom?

PamBio was founded in April 2014 by Abd Al-Roof Higazi and Dr. Nuha Higazi.

What was a significant funding event for PamBio?

In July 2016, PamBio raised $7M in a funding round, as reported by Globes. This funding was for their stroke treatment technology.

What is the total capital raised by PamBio?

PamBio has raised a total of $10M across two funding rounds.

What is the core technology behind PamBio's solution?

PamBio's solution for ICH drug treatment is an inactive recombinant mutant-tPA protein, designed to be a competitive inhibitor to native-tPA with dual antifibrinolytic and neuroprotective effects.